Suzuki E, Tsujimoto G, Tamura K, Hashimoto K
Department of Pharmacology, Yamanashi Medical College, Japan.
Mol Pharmacol. 1990 Nov;38(5):725-36.
Using the alpha 1-adrenoceptor subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta. The alpha 1-adrenoceptor alkylating agent CEC selectively inhibited the phasic component of the norepinephrine-induced contractile response, with little effect on the tonic component. The alpha 1-adrenoceptor occupancy-response relationship defined by the phenoxybenzamine inactivation method was rectangular hyperbolic for the tonic response, whereas that for the phasic response was linear, indicating the different degree of receptor reserve for the two responses. Radioligand binding studies with the nonselective alpha 1-adrenoceptor antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1). Moreover, alpha 1-adrenoceptor-mediated phosphatidylinositol (PI) hydrolysis was CEC sensitive, and fractional inactivation of alpha 1 receptors with CEC showed equivalent increments in the reduction of PI hydrolysis and phasic contractile response, suggesting that both responses are linearly related to the CEC-sensitive receptor sites. The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against alpha 1a-adrenoceptor-selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +/- 0.07 (n = 5) for WB4101 and 9.09 +/- 0.05 (n = 3) for 5-methyl-urapidil. However, the Schilod plots for these antagonists against norepinephrine were curvilinear. Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that alpha 1-adrenoceptor populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)
我们使用α1 - 肾上腺素能受体亚型选择性拮抗剂氯乙可乐定(CEC)、WB4101和5 - 甲基乌拉地尔,研究了兔主动脉中α1 - 肾上腺素能受体群体可能存在的异质性。α1 - 肾上腺素能受体烷基化剂CEC选择性抑制去甲肾上腺素诱导的收缩反应的时相成分,对张力成分影响很小。用酚苄明失活法确定的α1 - 肾上腺素能受体占有率 - 反应关系,对于张力反应呈矩形双曲线,而对于时相反应呈线性,表明两种反应的受体储备程度不同。用非选择性α1 - 肾上腺素能受体拮抗剂放射性配体125I - BE2254进行的放射性配体结合研究表明,兔主动脉中73 - 87%的结合位点对CEC敏感,它们对WB4101(pKd = 8.1)和5 - 甲基乌拉地尔(pKd = 7.1)均主要为低亲和力位点。此外,α1 - 肾上腺素能受体介导的磷脂酰肌醇(PI)水解对CEC敏感,用CEC对α1受体进行部分失活显示,PI水解减少和时相收缩反应减少有同等程度的增加,表明两种反应都与CEC敏感的受体位点呈线性相关。竞争性拮抗剂WB4101和5 - 甲基乌拉地尔对α1a - 肾上腺素能受体选择性激动剂甲氧明诱导的收缩反应的Schild图呈线性,斜率与1无显著差异,WB4101的pA2为9.07±0.07(n = 5),5 - 甲基乌拉地尔的pA2为9.09±0.05(n = 3)。然而,这些拮抗剂对去甲肾上腺素的Schild图是曲线。在双受体系统中对这些曲线Schild图进行计算机辅助分析表明,负责收缩反应的α1 - 肾上腺素能受体群体主要(约80 - 90%)是这两种拮抗剂的低亲和力位点(WB4101的pKd约为8.1,5 - 甲基乌拉地尔的pKd约为7.1),一小部分群体(约10 - 20%)是高亲和力位点(WB4101和5 - 甲基乌拉地尔的pKd约为9.1),这与放射性配体结合研究结果高度一致。(摘要截短于400字)